Monoclonal antibody

Intraveinous route of administration

Monthly administration or dependant on a biomarker level

ENCEFA has identified a novel target, highly expressed in the brain and the immune system, whose expression increases with aging, and highly dysregulated in neurodegenerative diseases.

While drugs currently under development target a unique pathway at a time (frequently the anti-aggregation one), our antibody triggers very strong neuroprotective effects by regulating through its target autophagy, metabolism and inflammation, three main components of neurodegeneration.

Therefore, by its unprecedented broad and powerful effects, including preliminary results in post-conditioning (when disease is installed), ENCEFA's antibody represents a promising advance against neurodegenerative pathologies, facing the complexity of these pathologies. It is expected to be effective on a large population of patients suffering from diseases without any treatment available yet.